Abstract
Uncontrolled kallikrein activation is involved in diseases such as hereditary angioedema, bacterial septic shock and procedures such as cardiopulmonary bypass. Here we report a series of small molecule compounds that potently inhibit kallikrein activity in vitro. Kinetic studies indicate that some of these compounds are slow binding inhibitors of kallikrein with Ki final less than a nanomolar. The ability of these compounds to inhibit the activity of kallikrein was further confirmed in a plasma model by quantitating the release of bradykinin, an endogenous cleavage product of plasma kallikrein. To understand the inhibitory mechanism of the selected compounds toward kallikrein, the interactions between the selected compounds and kallikrein was explored using molecular modeling based on the information of crystal structures of TF/FVIIa and kallikrein. The information presented in the current study provides an initial approach to develop more selective and therapeutically useful small molecule inhibitors.
Keywords: Kallikrein, contact activation, bradykinin, inhibitor, modeling
Medicinal Chemistry
Title: Discovery of Highly Potent Small Molecule Kallikrein Inhibitors
Volume: 2 Issue: 6
Author(s): J. Zhang, R. Krishnan, C. S. Arnold, E. Mattsson, J. M. Kilpatrick, S. Bantia, A. Dehghani, B. Boudreaux, S. N. Gupta, P.L. Kotian, P. Chand and Y.S. Babu
Affiliation:
Keywords: Kallikrein, contact activation, bradykinin, inhibitor, modeling
Abstract: Uncontrolled kallikrein activation is involved in diseases such as hereditary angioedema, bacterial septic shock and procedures such as cardiopulmonary bypass. Here we report a series of small molecule compounds that potently inhibit kallikrein activity in vitro. Kinetic studies indicate that some of these compounds are slow binding inhibitors of kallikrein with Ki final less than a nanomolar. The ability of these compounds to inhibit the activity of kallikrein was further confirmed in a plasma model by quantitating the release of bradykinin, an endogenous cleavage product of plasma kallikrein. To understand the inhibitory mechanism of the selected compounds toward kallikrein, the interactions between the selected compounds and kallikrein was explored using molecular modeling based on the information of crystal structures of TF/FVIIa and kallikrein. The information presented in the current study provides an initial approach to develop more selective and therapeutically useful small molecule inhibitors.
Export Options
About this article
Cite this article as:
Zhang J., Krishnan R., Arnold S. C., Mattsson E., Kilpatrick M. J., Bantia S., Dehghani A., Boudreaux B., Gupta N. S., Kotian P.L., Chand P. and Babu Y.S., Discovery of Highly Potent Small Molecule Kallikrein Inhibitors, Medicinal Chemistry 2006; 2 (6) . https://dx.doi.org/10.2174/1573406410602060545
DOI https://dx.doi.org/10.2174/1573406410602060545 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Characteristics of Asian Mosquito Saliva Allergens for Specific Diagnoses and Effective Therapies
Current Protein & Peptide Science Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Use of Alternative Antiplatelet Agents for Clopidogrel Hypersensitivity
Current Vascular Pharmacology Drug Treatment of Metabolic Syndrome
Current Clinical Pharmacology Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety The Role of Antihistamine Drugs in Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Allergic and Pseudoallergic Reactions Induced by Glucocorticoids: A Review
Current Pharmaceutical Design Vasopeptidase Inhibition for Blood Pressure Control: Emerging Experience
Current Pharmaceutical Design Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging Association of Wheat Allergy and Coeliac Disease through Pediatric and Adult Age: A Review of Literature
Current Nutrition & Food Science Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti- Inflammatory Drugs: A Review
Current Drug Metabolism IgE-Mediated Hypersensitivity to Cephalosporins
Current Pharmaceutical Design Effects of Amine Oxidases in Allergic and Histamine-Mediated Conditions
Recent Patents on Inflammation & Allergy Drug Discovery An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy Efalizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial (Mini-Thematic Issue: Mold Allergens and Antigenic Epitopes Correlation with Fungal Diseases)
Current Protein & Peptide Science Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews